Biomarker analysis in advanced colorectal cancer patients treated with mFOLFOX6 plus bevacizumab or XELOX plus bevacizumab

Phase 2

• Conditions: Advanced colorectal cancer

• Registration Number: JPRN-UMIN000012442
• Lead Sponsor: West Japan Oncology Group

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2013-11-29
• Study Completion: 2018-04-09
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

Not provided

Exclusion Criteria

1. Brain metastasis with symptoms. 2. Massive ascites, pleural effusion or pericardial effusions that need medical treatment. 3. Active another malignancies 4. Non-healing wound (excluding central venous port) 5. Major surgical procedure within 28 days prior to enroll in this study. (Minor surgical procedure within 14 days prior to enroll in this study.) 6. Other serious concomitant disease. a) intestinal obstruction b) History of arterial thromboembolic events such as unstable angina, myocardial infarction, and cerebrovascular accidents within 6 months. c) Clinically significant cardiovascular disease d) Severe pulmonary fibrosis, interstitial pneumonia or COPD on chest XP e) Uncontrollable hypertension f) Uncontrollable diabetes mellitus g) Active peptic ulcer h) Uncontrollable diarrhea i) Hemorrhagic Diathesis j) HIV infection 7. Regular use of corticosteroid. 8. Peripheral neuropathy>=Grade 1 at baseline. 9. Active local or systemic infectious disease. 10. History of serious hypersensitivity. 11. Blood tests positive for HBs antigen. 12. Uncontrollable severe mental disorder. 13. Pregnant or lactating female. 14. Judged inappropriate by the investigators

Study & Design

• Study Type: Interventional
• Study Design: Not specified